<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00922792</url>
  </required_header>
  <id_info>
    <org_study_id>NN7128-3700</org_study_id>
    <secondary_id>2009-010080-16</secondary_id>
    <nct_id>NCT00922792</nct_id>
  </id_info>
  <brief_title>Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B</brief_title>
  <official_title>An Open, Non-Randomised Single and Multiple Dose Trial Investigating the Safety and Pharmacokinetics of Intravenous Administration of Long Acting rFVIIa (LA-rFVIIa) in Patients With Haemophilia A and B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to investigate the
      safety and pharmacokinetics (the effect of the body on the investigated drug) of long acting
      activated recombinant human factor VII (LA-rFVIIa) in patients with haemophilia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>after 1 and 2 weeks after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of serious adverse events</measure>
    <time_frame>after 1, 2 and 6-10 weeks after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of MESIs (Medical Event of Special Interest)</measure>
    <time_frame>after 1, 2 and 6-10 weeks after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of ocurrence of neutralising antibodies against FVII and/or LA-rFVIIa</measure>
    <time_frame>after 2 and 6-10 weeks after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters based on FVIIa activity. The pharmacokinetic parameters to be reported are: AUC(0-48h), AUC(0-t) and AUC, C10min, Vz, CL, and t½</measure>
    <time_frame>from time of dosing up to 72 hours after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Congenital Bleeding Disorder</condition>
  <condition>Haemophilia A</condition>
  <condition>Haemophilia B</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activated recombinant human factor VII, long acting</intervention_name>
    <description>Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>activated recombinant human factor VII, long acting</intervention_name>
    <description>Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Haemophilia A or B

          -  Bodyweight max 100 kg

          -  Body Mass Index (BMI) max 30 kg/m2

          -  Adequate venous access

        Exclusion Criteria:

          -  Known or suspected allergy to trial product(s) or related products (including
             NovoSeven®)

          -  The receipt of any investigational product within 30 days prior to enrolment in this
             trial

          -  Receipt of Immune Tolerance Induction (ITI) within the last 1 month prior to
             participation in this trial

          -  The receipt of any haemostatic treatment for control of a bleeding episode within the
             last 5 days prior to administration of trial product

          -  Receipt of FVIII or FIX replacement therapy within 48 hours prior to trial product
             administration

          -  Known pseudo tumours

          -  Congenital or acquired coagulation disorders other than haemophilia A or B

          -  Any major and/or orthopaedic surgery within one month prior to trial start

          -  Advanced atherosclerotic disease (defined as known history of ischemic heart disease,
             ischemic stroke, etc.)

          -  Clinical signs of renal dysfunction

          -  Use of platelet inhibitors, including NSAIDs, one week prior to administration of
             trial drug

          -  Use of non-prescribed opiate substances
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 17, 2009</study_first_posted>
  <last_update_submitted>May 12, 2016</last_update_submitted>
  <last_update_submitted_qc>May 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Hemophilia B</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

